QIAGEN has expanded its COVID-19 testing portfolio with a new sequencing solution, the QIAseq DIRECT SARS-CoV-2. Reducing turnaround time to as few as 4 hours, it increases the number of samples per sequencer to over 6,000 samples on the highest throughput instruments. This solution is supported by the new QIAGEN Digital Insights CoV-2 insights service, a cloud-based solution designed to assist labs in the analysis and interpretation of viral datasets.

• QIAGEN